Delayed fatal neurotoxicity in post CAR-T cell therapy for multiple myeloma, a case report
{{output}}
Anti-BCMA CAR T-cell therapy, specifically ciltacabtagene autoleucel, has significantly improved outcomes for relapsed/refractory multiple myeloma (RRMM). While early-onset immune-effector cell-associated neurotoxicity syndrome (ICANS) is a recognized complica... ...
